Wilkinson Global Asset Management LLC Lowers Holdings in Amgen Inc. $AMGN

Wilkinson Global Asset Management LLC reduced its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 26.9% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 136,508 shares of the medical research company’s stock after selling 50,357 shares during the period. Amgen accounts for about 3.9% of Wilkinson Global Asset Management LLC’s investment portfolio, making the stock its 12th largest position. Wilkinson Global Asset Management LLC’s holdings in Amgen were worth $49,432,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also modified their holdings of the company. High Note Wealth LLC grew its holdings in Amgen by 5.8% in the fourth quarter. High Note Wealth LLC now owns 508 shares of the medical research company’s stock valued at $166,000 after purchasing an additional 28 shares during the period. TAGStone Capital Inc. raised its stake in Amgen by 0.7% during the fourth quarter. TAGStone Capital Inc. now owns 4,129 shares of the medical research company’s stock worth $1,351,000 after purchasing an additional 28 shares during the period. Verus Capital Partners LLC boosted its holdings in shares of Amgen by 2.3% in the 4th quarter. Verus Capital Partners LLC now owns 1,231 shares of the medical research company’s stock valued at $403,000 after purchasing an additional 28 shares during the last quarter. Destination Wealth Management boosted its holdings in shares of Amgen by 2.1% in the 4th quarter. Destination Wealth Management now owns 1,393 shares of the medical research company’s stock valued at $456,000 after purchasing an additional 29 shares during the last quarter. Finally, Breakwater Capital Group boosted its holdings in shares of Amgen by 1.4% in the 1st quarter. Breakwater Capital Group now owns 2,039 shares of the medical research company’s stock valued at $717,000 after purchasing an additional 29 shares during the last quarter. 76.50% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, SVP Nancy A. Grygiel sold 2,970 shares of Amgen stock in a transaction dated Thursday, August 6th. The stock was sold at an average price of $402.16, for a total transaction of $1,194,415.20. Following the sale, the senior vice president directly owned 7,340 shares of the company’s stock, valued at approximately $2,951,854.40. The trade was a 28.81% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Rachna Khosla sold 1,252 shares of the business’s stock in a transaction dated Thursday, August 13th. The stock was sold at an average price of $416.43, for a total value of $521,370.36. Following the completion of the transaction, the senior vice president owned 6,404 shares in the company, valued at approximately $2,666,817.72. This trade represents a 16.35% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 6,222 shares of company stock valued at $2,540,926 over the last 90 days. Insiders own 0.85% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the company. Robert W. Baird upped their price objective on Amgen from $215.00 to $230.00 and gave the stock an “underperform” rating in a report on Wednesday, August 5th. Scotiabank lifted their target price on Amgen from $385.00 to $450.00 and gave the company an “outperform” rating in a report on Wednesday, August 5th. Erste Group Bank reissued a “hold” rating on shares of Amgen in a research report on Tuesday, May 5th. Barclays upped their price target on Amgen from $360.00 to $380.00 and gave the stock an “equal weight” rating in a research note on Friday. Finally, Royal Bank Of Canada raised their price objective on Amgen from $370.00 to $400.00 and gave the stock an “outperform” rating in a report on Wednesday, August 5th. One investment analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, fifteen have issued a Hold rating and three have issued a Sell rating to the company. According to data from MarketBeat.com, Amgen currently has a consensus rating of “Hold” and an average target price of $372.39.

Amgen Price Performance

Shares of AMGN stock opened at $419.38 on Tuesday. The company has a market capitalization of $226.73 billion, a PE ratio of 26.06, a price-to-earnings-growth ratio of 3.86 and a beta of 0.41. The firm has a fifty day simple moving average of $372.05 and a 200-day simple moving average of $359.47. The company has a current ratio of 1.37, a quick ratio of 1.13 and a debt-to-equity ratio of 4.44. Amgen Inc. has a twelve month low of $269.77 and a twelve month high of $421.79.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Tuesday, August 4th. The medical research company reported $6.29 earnings per share for the quarter, beating analysts’ consensus estimates of $5.62 by $0.67. Amgen had a net margin of 22.95% and a return on equity of 124.14%. The business had revenue of $10.05 billion during the quarter, compared to analyst estimates of $9.43 billion. During the same period last year, the business earned $6.02 EPS. The business’s revenue was up 9.5% on a year-over-year basis. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. Equities research analysts anticipate that Amgen Inc. will post 22.78 earnings per share for the current fiscal year.

Amgen Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, September 11th. Stockholders of record on Friday, August 21st will be paid a dividend of $2.52 per share. The ex-dividend date is Friday, August 21st. This represents a $10.08 annualized dividend and a dividend yield of 2.4%. Amgen’s dividend payout ratio (DPR) is currently 62.65%.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.